This publication was published more than 5 years ago. The state of knowledge may have changed.

Nuedexta for the treatment of pseudobulbar affect (in ALS patients)

Pseudobuldar affect is characterized by uncontrollable crying, laughter or other emotional displays. It can occur secondary to a neurological disorder or traumatic brain injury. The drug Nuedexta has been approved by the FDA in 2010 as a treatment option for pseudobulbar affect in patients with ALS or MS. However, in the EU Nuedexta has been deregistered since 2016 for market reasons according to the company. The question posed to the SBU Enquiry Service concerns what scientific studies that have documented the efficacy and safety of Nuedexta as a treatment of pseudobulbar affect in patients with ALS.

Reading time approx. 1 minute Published: Publication type:

SBU Enquiry Service

Consists of structured literature searches to highlight studies that can address questions received by the SBU Enquiry Service from Swedish healthcare or social service providers. We assess the risk of bias in systematic reviews and when needed also quality and transferability of results in health economic studies. Relevant references are compiled by an SBU staff member, in consultation with an external expert when needed.

Contact SBU
Published:

Search term(s)

Nuedexta dextrometorphan/quinidine pseudobulbar affect amyotrophic lateral sclerosis

Are there scientific studies on efficacy and safety of the drug Nuedexta (dextrometorphan/quinidine) for symptomatic treatment of pseudobulbar affect in patients with ALS?

Literature search

Literature search.pdf

Project group

Nathalie Peira och Sally Saad at SBU.

Page published
To top